ACE and COVID-19: However, other experimental evidence has shown a protective effect of RAAS inhibition in COVID‐19 patients,47 and, in a recent retrospective clinical study, the use of ACE inhibitors and ARBs was associated with lower overall mortality among hospitalised COVID‐19 patients with hypertension.48